< International Circulation>: Can you introduce to us any other new therapy， perhaps non-pharmacological therapies， that have been used recently to treat atrial fibrillation?

    Prof. Schneider:  To my knowledge we have included the most recent trials in our analysis that has just been published in the Journal of American Cardiology and there is a study， hopefully to be published called the ANTI-PAF trial， which looks at the effects of almacartan on patients with atrial fibrillation and on the development of atrial fibrillation.  This study uses early monitoring.  They used reveal units to record atrial fibrillation， which is the most sensitive way to detect atrial fibrillation and this is what is needed in the future.  We need to have studies with good detection of atrial fibrillation and then we will know which drugs are most effective.

bookbook

上一页  [1]  [2]  [3]  [4]